MOJ ISSN: 2373-4442MOJI

Immunology
Editorial
Volume 3 Issue 2 - 2016
Risk of Non-Mycobacterial Tuberculosis Infection Lurks Beneath the Water Surface
Shanthi Vadali*
Department of Pathology, University of Arkansas for Medical Sciences, USA
Received:May 01, 2016 | Published: May 03, 2016
*Corresponding author: Shanthi Vadali, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA, Tel: 337-302-4477; Email:
Citation: Vadali S (2016) Risk of Non-Mycobacterial Tuberculosis Infection Lurks Beneath the Water Surface. MOJ Immunol 3(2): 00086. DOI: 10.15406/moji.2016.03.00086

Keywords

Tuberculosis; HIV/AIDS; TB patients; NTM infections; HIV virus; Water Surface

Abbreviations

TB: Tuberculosis; BCG: Bacillus Calmette-Guérin; IGRA: Interferon Gamma Release Assay; NTB: Non-TB Mycobacterial Infections; MDR-TB: Multi-Drug Resistance; NTM: Non TB Mycobacterial

Editorial

Death from tuberculosis (TB) comes second to HIV/AIDS worldwide [1]. The question is, despite advancements made in early detection and diagnostic tests by Interferon Gamma Release Assay (IGRA) assays, why do people still die of TB? Clearly, the only licensed Bacillus Calmette-Guérin (BCG) vaccine is not effective in preventing the disease. According to WHO, in 2014, 9.6 million people were TB positive and 1.5 million died of TB globally. Out of these, 80% of the cases were from developing countries such as India, Indonesia, Nigeria, China, Pakistan and South Africa. Factors that contribute to such high rates of death are HIV/AIDS, multi-drug resistance (MDR-TB) and Non-TB mycobacterial infections (NTB). Globally, TB remains the most common cause of death in HIV patients.

HIV virus and TB bacteria can co-work together causing functional changes in T-cells and macrophages [2]. Another risk factor for increased TB related deaths is the multi-drug resistance to TB infection. In 2014, 480,000 TB patients worldwide developed Multi drug resistant TB (MDR-TB), TB that does not respond to isoniazid and rifampicin [3]. Often times, MDR-TB develops in patients due to use of poor quality medicines and premature treatment interruption. Length of treatment extending to years and the number of pills contribute to the non-conformity to treatment regimen in patients. Efforts made by TB alliance group have made possible a triple combination pill for TB called PaMZ (Pretomanid + Moxifloxacin + Pyrazinamide). PaMZ is under clinical trials which are expected to decrease the length and cost of TB treatment [4].

TB cases in United States have decreased by 2.2% in 2014, however, the risk of non TB mycobacterial (NTM) infection is reported to be increasing annually [5,6]. Non-Tuberculosis Mycobacterium (NTM) infections or MOTT (Mycobacterium other than tuberculosis) are caused by mycobacterial species other than Mycobacterium tuberculosis [7]. NTM infections are infections very common in immunocompromised patients and US alone has 10 million immunocompromised patients that are HIV positive, transplant patients and patients on steroid medications [8]. Unlike TB, Non-TB infection is transmitted through environmental exposure such as soil and water [9]. It is predicted that patients may be at a greater risk of NTM infection than TB in United States with prevalence in elderly women [10,11].

Longer hot bath showers can increase the risk of Non-TB infection [7]. Most prevalent Non-TB infectious microbes such as M. Avium complex, M. Smegmatisare known to form biofilms and to live in water pipelines for long years [12,13]. Currently, there are 150 species of Mycobacterium discovered, it is critical to recognize that these bacteria may cause pulmonary disease in both immunocompetent and immunocompromised patients [14]. A multipronged approach is often necessary to diagnose the mycobacterium agent, which include culture growth of NTM from one bronchoalveolar lavage, sputum samples, or culture from respiratory tissue demonstrating granulomatous histopathology [11]. The choice and extent of treatment depends on the mycobacterium species and often times may need surgery depending on the disease severity. At present, there are substantial gaps in regards to identification and treatment of the NTM disease; nevertheless, it is becoming increasingly evident that the incidence of NTM infections surpasses that of TB infections in developed countries.

References

  1. CDC (2014) Data and Statistics. Centers for Disease Control and Prevention.
  2. Andrzej Pawlowski, Marianne Jansson, Markus Sköld , Martin E R , Gunilla Källenius (2012) Tuberculosis and HIV Co-Infection. PLoS Pathog 8(2): e1002464.
  3. WHO (2015) What is multidrug-resistant tuberculosis (MDR-TB) and how do we control it? World Health Organization.
  4. Clinicaltrails.gov (2014) shortening treatment by advancing Novel drugs. Global Alliance for TB Drug Development.
  5. Kenneth NO, Pamela AS, Tanya G, Darshana B, Steve H, et al. (2010) Effectiveness And Toxicity Of Inhaled Amikacin For Refractory Pulmonary Nontuberculous Mycobacterial Disease. ATS Journals 182: 970-976.
  6. du Moulin GC, Sherman IH, Hoaglin DC, Stottmeier KD (1985) Mycobacterium avium complex, an emerging pathogen in Massachusetts. J Clin Microbiol 22(1): 9-12.
  7. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, et al. (2010) Pulmonary Nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 182(7): 977-982.               
  8. Laura HK (2008) The growing number of immunocompromised. Bulletin of the Atomic Scientists.
  9. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL (2009) Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 49(12): e124-e129.
  10. Johnson MM, Odell JA (2014) Nontuberculous mycobacterial pulmonary infections. J Thorac Dis 6(3): 210-220.
  11. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR (2012) Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 185(8): 881-886.
  12. JoAnn H, William EA, Jeffrey A, Larry CB, Stanley B, et al. (2001) Genome of the Bacterium Streptococcus pneumoniae Strain R6 J Bacteriol 183(19): 5709-5717.
  13. Yamazaki Y, Danelishvili L, Wu M, Hidaka E, Katsuyama T (2006) The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells. Cell Microbiol 8(5): 806-814.
  14. www.bacterio.cict.fr/m/mycobacterium.html
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy